Return
Biography

Prof. Stephen L. CHAN

The Chinese University of Hong Kong, Hong Kong (China)


Email: L_chan@clo.cuhk.edu.hk


Qualifications


Ph.D., The Chinese University of Hong Kong


Publications (selected)

  1. Chan SL, Mok T. PARP inhibition in breast and ovarian cancers. Lancet. 2010; 376:211-213.
  2. Chan SL, Mo F, Johnson PJ, Hui EP, Ma BB, Ho WM, Lam KC, Chan AT, Mok TS, Yeo W. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiological response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009; 27:446-452.
  3. Wong VW*, Chan SL*, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, AT Chan, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. (*equal contribution). J Clin Oncol. 2010; 28:1660-1665.
  4. Chan SL, Mo FK, Wong CS, Chan CM, Leung LK, Hui EP, Ma BB, Chan AT, Mok TS, Yeo W. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer 2012.118:3984-9.
  5. Chan SL, Mo FK, Wong VW, Liem GS, Wong GL, Chan VT, Poon MC, Loong HH, Yeo W, Chan AT, Mok TS, Chan HL. Use of antiviral therapy in surveillance: impact on outcome hepatitis B-related hepatocellular carcinoma. Liver Internat. 2011; 32:271-8.
  6. Chan SL. Commentary: the impact of compact lipiodolisation following transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 2012; 36: 74-5.
  7. Chan SL, Ma BB. Novel systemic therapeutic for nasopharyngeal carcinoma. Expert Opin Ther Targets 2012;16 Suppl 1:S63-8.
  8. Chan SL, Chan ATC, Yeo W. Role of alpha-fetoprotein in hepatocellular carcinoma: Prognostication, treatment monitoring or both. Future Oncol. 2009; 5:889-899.
  9. Chan SL, Mo FK, Johnson PJ, Liem GS, Chan TC, Poon MC, Ma BB, Leung TW, Lai PB, Chan AT, Mok TS, Yeo W. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol 2011;26:340-7.
  10. Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: present and future. J Gastroenterol Hepatol 2012;27:862-72.
  11. Chan SL, Wong CH, Lau CPY, Zhou Q, Lui VWY, Ma BB, Chan AT, Yeo W. Preclinical evaluation of combined TKI258 and RAD001 in hepatocellular carcinoma. Cancer Chemo Pharma. Doi: 10.1007/s00280-013-2139-4
  12. Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr Oncol Rep. 2012;14:257-66.
  13. Ma BB, Chan SL. Hong Kong Cancer Institute/AACR International Conference. Infection and cancer: biology, therapeutics and prevention. IDrugs. 2009; 12:69-72.
  14. Yeo W, Mo FK, Hui P, Chan SL. Need of stratifying patients according to severity of underlying liver disease for hepatocellular carcinoma patients undergoing systemic therapy trials. Contemp Clin Trials 2010;31:135.
  15. Chan SL, Yeo W. Selecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how? Asia Pac J Clin Oncol 2013; 9:2-5.
  16. Chan SL, Johnson P. Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective. Asia Pac J Clin Oncol 2012;8:111-4.
  17. Chan LC, Chiu SK, Chan SL. Stereotactic radiotherapy for hepatocellular carcinoma: report of a local single-centre experience. Hong Kong Med J 2011;17:112-118.
  18. Ma BB, Chan SL, Ho WM, Lau W, Mo F, Hui EP, Chan C, Poon A, Dattatray RD, Wong SC, King AD, Ahuja A, Chan AT. Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: Correlation With Serum Amphiregulin and Transforming Growth Factor Alpha. Cancer, 2013;119:4145-53.
  19. Chan SL, Mo F, Johnson PJ, Siu DY, Chan MH, Lau WY, Lai PB, Lam CW, Yeo W, Yu SC. Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB (Oxford), doi: 10.1111/hpb.12146